An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis

Geake, James B.; Reid, David W.; Currie, Bart J.; Bell, Scott C.

doi:10.1186/s12890-015-0109-9

Table 3 Eradication strategies

From: An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis

Patient	Duration of infection prior to treatment	Induction		Consolidation
		Treatment	Duration	Treatment	Duration
Successful eradication
16 (Corral, 2008) [10]	Unknown – lived in BVI	Meropenem 2 g tds	19 days	TMP/SMX 960 mg bd	19 days
		Meropenem 2 g tds		Minocycline 100 mg bd
		Minocycline 100 mg bd		Minocycline 100 mg bd
		Minocycline 100 mg bd		Tobramycin (neb)^a 80 mg bd
20 (O’Sullivan, 2011) [13]	3 months	Imipenem	14 days	Meropenem (neb)	28 days
20 (O’Sullivan, 2011) [13]	3 months	Ceftazidime	14 days	TMP/SMX 960 mg bd	2 years
4 (Visca, 2001) [15]	12 months	Ceftazidime	42 days	TMP/SMX 960 mg bd	210 days
		TMP/SMX 960 mg bd		Doxycycline
		TMP/SMX 960 mg bd		Chloramphenicol
13 (Asiah, 2006) [8]	12 months	Ceftazidime	56 days	TMP/SMX 960 mg bd	112 days
13 (Asiah, 2006) [8]	12 months	TMP/SMX 960 mg bd	56 days	Doxycycline	112 days
22 (Radhakrishna, 2014) [17]	7 years	Meropenem 2 g tds	Approx 56 days	Doxycycline followed by amoxycillin/clavulanic acid (doxycycline allergy)	12 months
		Ceftazidime 3 g tds
		Tobramycin (neb) 80 mg bd
		TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 1	Unknown	Ceftazidime	14 days	TMP/SMX 960 mg bd	90 days
9 (Holland, 2002) [16] Infection 1	Unknown	TMP/SMX 960 mg bd	14 days	TMP/SMX 960 mg bd	90 days
9 (Holland, 2002) [16] Infection 2	1 month	Ceftazidime	21 days	TMP/SMX 960 mg bd	90 days
9 (Holland, 2002) [16] Infection 2	1 month	TMP/SMX 960 mg bd	21 days	TMP/SMX 960 mg bd	90 days
9 (Holland, 2002) [16] Infection 3	1-2 months	Ceftazidime	14 days	TMP/SMX 960 mg bd	90 days
9 (Holland, 2002) [16] Infection 3	1-2 months	TMP/SMX 960 mg bd	14 days	TMP/SMX 960 mg bd	90 days
Failed Eradication
8 (O’Carroll, 2003) [12]	4 months	Meropenem 2 g tds	56 days	None
8 (O’Carroll, 2003) [12]	4 months	Ceftazidime 3 g tds	56 days	None
17	6-12 months	Ceftazidime 3 g tds	14 days	TMP/SMX 960 mg bd	84 days
17	6-12 months	TMP/SMX 960 mg bd	14 days	TMP/SMX 960 mg bd	84 days
23	>10 months	Ceftazidime 3 g tds	21 days	Unknown (patient moved to Malaysia)
		TMP/SMX 960 mg bd
		Tobramycin 5 mg/kg
3 (Schülin, 2001) [14]	6 years	Unspecified antipseudomonal antibiotics	14 days	No (exacerbations directed against PsA)
14 (Barth, 2007) [9]	>18 months	Pipracillin/clavulanate	21 days	Meropenem 2 g tds	21 days
		Tobramycin 5 mg/kg		Ceftazidime 3 g tds
				Amikacin
				TMP/SMX 960 mg bd
15	>8 years	Meropenem 2 g tds	14 days	TMP/SMX 960 mg bd	126 days
		Tobramycin		Minocycline 100 mg bd
		Tobramycin		Meropenem (neb)
18 (1^st attempt)	2 months	Ceftazidime 1.5 g tds	14 days	Infection not cleared therefore 2^nd course of IV antibiotics
		Tobramycin 300 mg
		Amoxycillin/Clavulanic acid 900 mg
18 (2^nd attempt)	2 months	Meropenem	84 days	TMP/SMX 960 mg bd	Long term
		Ceftazidime		Doxycycline
		Amoxycillin/Clavulanic acid		Doxycycline
6 (Holland, 2002) [16]	>4 years	Ceftazidime 50 mg/kg	120 days	None (exacerbations directed against B. pseudomallei)
		Piperacillin 50 mg/kg
		Amoxycillin/Clavulanic acid
7 (Holland, 2002) [16]	>5 years			TMP/SMX 960 mg bd	4 years
1^st isolation	>5 years			TMP/SMX 960 mg bd	4 years
7 (Holland, 2002) [16]	>9 years	Imipenem	20 days	TMP/SMX 960 mg bd	19 days
2^nd isolation		Piperacillin/Clavulanic acid	42 days	Tetracycline	30 days
2^nd isolation		Piperacillin/Clavulanic acid	42 days	Meropenem/TMP/SMX	>30 days
11 (Holland, 2002) [16]	3 months	Ceftazidime	14 days	TMP/SMX 960 mg bd	330 days
11 (Holland, 2002) [16]	3 months	Tobramycin	14 days	TMP/SMX 960 mg bd	330 days
21	1 month	Meropenem 2 g tds	42 days	Tobramycin (neb) 300 mg bd	42 days
		Ceftazidime 3 g tds		TMP/SMX 960 mg bd
		Tobramycin 7 mg/kg		TMP/SMX 960 mg bd

Success of eradication for patient 24 and patient 25 unknown
^aneb = nebulized

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Pulmonary Medicine

Contact us